Pulmonary Rehabilitation for Adults with Chronic Respiratory Disease: An Official American Thoracic Society Clinical Practice Guideline

Abstract Background Despite the known benefits of pulmonary rehabilitation (PR) for patients with chronic respiratory disease, this treatment is underused. Evidence-based guidelines should lead to greater knowledge of the proven benefits of PR, highlight the role of PR in evidence-based health care, and in turn foster referrals to and more effective delivery of PR for people with chronic respiratory disease. Methods The multidisciplinary panel formulated six research questions addressing PR for specific patient groups (chronic obstructive pulmonary disease [COPD], interstitial lung disease, and pulmonary hypertension) and models for PR delivery (telerehabilitation, maintenance PR). Treatment effects were…

• P
  Pfizer
• A
  AstraZeneca
• G
  GlaxoSmithKline
• S
  Sanofi
• CF
  COPD Foundation
• MU
  McGill University
• ER
  European Respiratory Society
• S
  Sunovion
• CP
  Covis Pharma
• M
  Mylan
• V
  Veracyte
• CL
  Canadian Lung Association
• NI
  National Institute for Health and Care Research
• DO
  Department of Health and Social Care
• TS
  Thoracic Society of Australia and New Zealand
• UO
  University of Sydney
• MO
  Ministry of Health, British Columbia
• G
  Grifols
• NI
  National Institutes of Health
• CI
  Canadian Institutes of Health Research
• FD
  Fonds de Recherche du Québec - Santé
• MR
  Medical Research Council
• NH
  National Health and Medical Research Council
• FO
  Faculty of Medicine and Health, University of Sydney
• NH
  National Heart, Lung, and Blood Institute